CN111164429B - 预测对fgf-18化合物反应性的炎性生物标志物 - Google Patents
预测对fgf-18化合物反应性的炎性生物标志物 Download PDFInfo
- Publication number
- CN111164429B CN111164429B CN201880063173.4A CN201880063173A CN111164429B CN 111164429 B CN111164429 B CN 111164429B CN 201880063173 A CN201880063173 A CN 201880063173A CN 111164429 B CN111164429 B CN 111164429B
- Authority
- CN
- China
- Prior art keywords
- fgf
- treatment
- metalloproteinases
- cartilage
- degraded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17194169 | 2017-09-29 | ||
| EP17194169.3 | 2017-09-29 | ||
| EP18169317 | 2018-04-25 | ||
| EP18169317.7 | 2018-04-25 | ||
| PCT/EP2018/076391 WO2019063756A1 (en) | 2017-09-29 | 2018-09-28 | INFLAMMATORY BIOMARKERS FOR PREDICTING REACTIVITY TO FGF-18 COMPOUND |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111164429A CN111164429A (zh) | 2020-05-15 |
| CN111164429B true CN111164429B (zh) | 2024-08-09 |
Family
ID=63722379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880063173.4A Active CN111164429B (zh) | 2017-09-29 | 2018-09-28 | 预测对fgf-18化合物反应性的炎性生物标志物 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11467169B2 (https=) |
| EP (1) | EP3688468B1 (https=) |
| JP (1) | JP7418324B2 (https=) |
| CN (1) | CN111164429B (https=) |
| AU (1) | AU2018343980B2 (https=) |
| CA (1) | CA3075713A1 (https=) |
| DK (1) | DK3688468T3 (https=) |
| ES (1) | ES2918249T3 (https=) |
| HR (1) | HRP20220737T1 (https=) |
| HU (1) | HUE058848T2 (https=) |
| IL (1) | IL273574B2 (https=) |
| LT (1) | LT3688468T (https=) |
| PL (1) | PL3688468T3 (https=) |
| RS (1) | RS63292B1 (https=) |
| SI (1) | SI3688468T1 (https=) |
| WO (1) | WO2019063756A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016211950A1 (en) | 2015-01-29 | 2017-07-13 | Ares Trading S.A. | Immunoassays for high positively charged proteins |
| IL273613B2 (en) | 2017-09-29 | 2026-02-01 | Merck Patent Gmbh | Metabolic biomarkers for predicting response to FGF-18 compound |
| SI3688468T1 (sl) | 2017-09-29 | 2022-08-31 | Merck Patent Gmbh | Vnetni biomarkerji za predvidevanje odzivov na spojino FGF-18 |
| IL281333B2 (en) | 2018-09-10 | 2025-11-01 | Merck Patent Gmbh | A method for reducing risk in a clinical trial |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104736723A (zh) * | 2012-08-06 | 2015-06-24 | 默克专利有限公司 | 用于预测对fgf-18化合物的响应性的遗传标记 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2339002A1 (en) | 1996-10-16 | 2011-06-29 | ZymoGenetics, Inc. | Fibroblast growth factor homologs |
| ES2493840T3 (es) | 2002-10-07 | 2014-09-12 | Zymogenetics, Inc. | Procedimiento de administración de FGF-18 |
| AU2003287697A1 (en) | 2002-11-08 | 2004-06-03 | Barnes-Jewish Hospital | Uncoupled collagen synthesis and degradation assays |
| AU2005314438B2 (en) | 2004-12-10 | 2012-03-29 | Zymogenetics, Inc. | FGF18 production in prokaryotic hosts |
| US8224579B2 (en) | 2005-06-17 | 2012-07-17 | The Brigham And Women's Hospital, Inc. | Method of diagnosing osteoarthritis |
| HRP20120643T1 (hr) | 2006-08-25 | 2012-08-31 | Ares Trading S.A. | Liječenje poremećaja hrskavice sa fgf-18 |
| JP2009257842A (ja) | 2008-04-14 | 2009-11-05 | Ttc:Kk | 変形性関節症の検査方法及び診断用キット |
| JP5762282B2 (ja) | 2008-05-02 | 2015-08-12 | インタールーキン ジェネティクス， インコーポレイテッド | 変形性関節症に関連する状態に対する遺伝的素因の検出 |
| US20090299769A1 (en) | 2008-05-29 | 2009-12-03 | Nordic Bioscience Imaging A/S | Prognostic osteoarthritis biomarkers |
| US20120115137A1 (en) | 2010-08-31 | 2012-05-10 | Kornman Kenneth S | Methods of Predicting Osteoarthritis |
| TWI527590B (zh) | 2011-06-17 | 2016-04-01 | 艾瑞斯貿易公司 | Ｆｇｆ－１８之凍乾調配物 |
| AU2013301607B2 (en) | 2012-08-06 | 2018-10-18 | Merck Patent Gmbh | Prognosis biomarkers in cartilage disorders |
| CA2931978A1 (en) * | 2013-12-02 | 2015-06-11 | Abbvie Inc. | Compositions and methods for treating osteoarthritis |
| KR102622290B1 (ko) | 2013-12-24 | 2024-01-05 | 아레스 트레이딩 에스.아. | 크실로글루칸 겔 중의 fgf-18 제형물 |
| ES2806026T3 (es) | 2013-12-24 | 2021-02-16 | Ares Trading Sa | Formulación de FGF-18 en hidrogeles de alginato/colágeno |
| HUE040350T2 (hu) * | 2014-02-20 | 2019-03-28 | Merck Patent Gmbh | FGF-18 vegyületadagoló étrend |
| MX2016010873A (es) | 2014-02-20 | 2016-11-17 | Merck Patent Gmbh | Factor de crecimiento de fibroblastos 18 en los procedimientos para el trasplante de injertos y para ingenieria de tejidos. |
| JP6510547B2 (ja) | 2014-02-20 | 2019-05-08 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｆｇｆ−１８を含むインプラント |
| AU2016211950A1 (en) | 2015-01-29 | 2017-07-13 | Ares Trading S.A. | Immunoassays for high positively charged proteins |
| MX380092B (es) | 2015-11-06 | 2025-03-11 | Samumed Llc | Tratamiento de la osteoartritis. |
| US9983214B2 (en) | 2016-04-15 | 2018-05-29 | Esm Technologies, Llc | Method for evaluating articular joint therapeutics |
| SI3688468T1 (sl) | 2017-09-29 | 2022-08-31 | Merck Patent Gmbh | Vnetni biomarkerji za predvidevanje odzivov na spojino FGF-18 |
| IL273613B2 (en) | 2017-09-29 | 2026-02-01 | Merck Patent Gmbh | Metabolic biomarkers for predicting response to FGF-18 compound |
| IL281333B2 (en) | 2018-09-10 | 2025-11-01 | Merck Patent Gmbh | A method for reducing risk in a clinical trial |
-
2018
- 2018-09-28 SI SI201830693T patent/SI3688468T1/sl unknown
- 2018-09-28 WO PCT/EP2018/076391 patent/WO2019063756A1/en not_active Ceased
- 2018-09-28 US US16/650,878 patent/US11467169B2/en active Active
- 2018-09-28 LT LTEPPCT/EP2018/076391T patent/LT3688468T/lt unknown
- 2018-09-28 CN CN201880063173.4A patent/CN111164429B/zh active Active
- 2018-09-28 HU HUE18782012A patent/HUE058848T2/hu unknown
- 2018-09-28 AU AU2018343980A patent/AU2018343980B2/en active Active
- 2018-09-28 IL IL273574A patent/IL273574B2/en unknown
- 2018-09-28 ES ES18782012T patent/ES2918249T3/es active Active
- 2018-09-28 JP JP2020517797A patent/JP7418324B2/ja active Active
- 2018-09-28 CA CA3075713A patent/CA3075713A1/en active Pending
- 2018-09-28 EP EP18782012.1A patent/EP3688468B1/en active Active
- 2018-09-28 HR HRP20220737TT patent/HRP20220737T1/hr unknown
- 2018-09-28 RS RS20220541A patent/RS63292B1/sr unknown
- 2018-09-28 DK DK18782012.1T patent/DK3688468T3/da active
- 2018-09-28 PL PL18782012.1T patent/PL3688468T3/pl unknown
-
2022
- 2022-09-01 US US17/929,261 patent/US12332250B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104736723A (zh) * | 2012-08-06 | 2015-06-24 | 默克专利有限公司 | 用于预测对fgf-18化合物的响应性的遗传标记 |
Non-Patent Citations (3)
| Title |
|---|
| A.S. Siebuhr et al.Identification and characterisation of osteoarthritis patients with inflammation derived tissue turnover.《Osteoarthritis and Cartilage》.2014,第22卷(第1期),第45页. * |
| Clinical Trial Protocol;Merck KGaA et al;Phase II Trial of Sprifermin in Knee OA;第1页 * |
| Identification and characterisation of osteoarthritis patients with inflammation derived tissue turnover;A.S. Siebuhr et al;《Osteoarthritis and Cartilage》;20141231;第22卷(第1期);第44-50页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| RS63292B1 (sr) | 2022-06-30 |
| HRP20220737T1 (hr) | 2022-09-02 |
| IL273574B1 (en) | 2024-09-01 |
| AU2018343980A1 (en) | 2020-04-02 |
| AU2018343980B2 (en) | 2025-04-10 |
| ES2918249T3 (es) | 2022-07-14 |
| EP3688468B1 (en) | 2022-03-16 |
| LT3688468T (lt) | 2022-06-27 |
| US12332250B2 (en) | 2025-06-17 |
| US20230258659A1 (en) | 2023-08-17 |
| PL3688468T3 (pl) | 2022-07-18 |
| US11467169B2 (en) | 2022-10-11 |
| IL273574B2 (en) | 2025-01-01 |
| SI3688468T1 (sl) | 2022-08-31 |
| WO2019063756A1 (en) | 2019-04-04 |
| IL273574A (en) | 2020-05-31 |
| CA3075713A1 (en) | 2019-04-04 |
| JP7418324B2 (ja) | 2024-01-19 |
| EP3688468A1 (en) | 2020-08-05 |
| CN111164429A (zh) | 2020-05-15 |
| DK3688468T3 (da) | 2022-06-20 |
| JP2020535423A (ja) | 2020-12-03 |
| HUE058848T2 (hu) | 2022-09-28 |
| US20210231680A1 (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12332250B2 (en) | Inflammatory biomarkers for predicting responsiveness to FGF-18 compound | |
| US12332251B2 (en) | Metabolic biomarkers for predicting responsiveness to FGF-18 compound | |
| JP7568614B2 (ja) | 変形性関節症の治療のための富化戦略において有用なマーカー | |
| HK40058829B (en) | Markers useful in enrichment strategies for the treatment of osteoarthritis | |
| HK40058829A (en) | Markers useful in enrichment strategies for the treatment of osteoarthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |